Search
Prazosin
go.drugbank.com/drugs/DB00457ApprovedInvestigationalPrazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988.[L5828] It belongs to the class of drugs known as alpha-1 antagonists. … Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares.[A176618, A176621, A176624]
Acetylcholine
go.drugbank.com/drugs/DB03128ApprovedInvestigationalIt is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications. … Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in
Products: Miochol E, MIOCHOL EAuranofin
go.drugbank.com/drugs/DB00995ApprovedInvestigationalHeme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties.
Almasilate
go.drugbank.com/drugs/DB13595ApprovedAlmasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. … However its therapeutic efficacy is not comparable to other approved antacids, as it is no more effective in neutralizing acid and binding bile salts than other conventional antacids [A27138].
Panitumumab
go.drugbank.com/drugs/DB01269ApprovedInvestigationalThis drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.[L17663]
Anthoxanthum odoratum
go.drugbank.com/drugs/DB14163ApprovedAnthoxanthum odoratum allergenic extract is used in allergenic testing.
Bleomycin
go.drugbank.com/drugs/DB00290ApprovedInvestigationalIt inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
Pralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigationalAlthough multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated … [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment
Etravirine
go.drugbank.com/drugs/DB06414ApprovedInvestigationalIn 2013, reports of Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) in the setting of immune reconstitution, as well as more in depth information about the development … On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg.
Hemoglobin
go.drugbank.com/drugs/DB04945ApprovedInvestigationalWithdrawnThe respiratory protein of the red blood cells. It consists primarily of globin and heme.